# Surgify Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surgify-medical

- Industry: Medical Devices & Equipment
- Headquarters: Espoo, Finland
- Website: www.surgifymedical.com
- Total disclosed funding: $11M
- Latest round: Series A (May 9, 2025)
- Investors on record: 7

## About

Surgify Medical Oy, based in Finland, develops innovative surgical technologies, notably the Surgify Halo™, which enhances precision in bone surgeries and improves overall surgical safety.Surgify Medical Oy specializes in advanced surgical technology, with its headquarters located in Espoo, Finland. Founded in 2017 by Jukka Kreander, Nicolas Hubert, Shahab Haeri, and Visa Sippola, the company has completed a total of 4 deals. Most recently, on May 9, 2025, Surgify raised EUR 7 million in a Series A funding round led by ZEISS Ventures, with participation from the European Innovation Council and other investors. This funding round represents the total amount the company has raised to date.Surgify Medical Oy focuses on developing surgical technologies, with its flagship product being the Surgify Halo™. This device is engineered to facilitate safer and more accurate bone cutting within surgical procedures. The Surgify Halo™ targets orthopedic surgeons and medical facilities engaged in complex bone surgeries, thus benefiting patients needing such interventions. The company's products are distributed in various markets, including the United States and select international regions.In the most recent fiscal year 2023, Surgify Medical Oy reported a revenue of EUR 42,137.60 from the sales of the Surgify Halo™ to medical institutions and surgical centers. The company operates on a B2B model, establishing agreements with healthcare providers that govern pricing and terms for their surgical technology, thereby contributing to its revenue streams. However, the EBITDA for 2023 was reported at EUR -665,896.90, indicating a loss for the year.The recent funding of EUR 7 million will be utilized by Surgify Medical Oy to enhance the safety of bone surgeries through the development of tissue-selective technology. The company plans to expand its operations into new markets within the European Union and the United States. Specific new product developments and launch timelines have not been disclosed, but the focus remains on improving surgical accuracy and safety, aligning with their growth strategy.

## Funding rounds

- Series A, May 9, 2025, $7.9M — European Innovation Council, Cascara Ventures, ZEISS Ventures
- Series C, Dec 1, 2020, $1.7M — Innovestor
- Seed, Oct 25, 2017, $1.2M — Butterfly Ventures, Cascara Ventures, Merkatura AB, FRIIH GmBH

## Investors

- Butterfly Ventures (https://capitalatlas.ai/funds/butterfly-ventures) — Seed
- Cascara Ventures (https://capitalatlas.ai/funds/cascara-ventures) — Seed, Series A
- Merkatura AB — Seed
- FRIIH GmBH (https://capitalatlas.ai/funds/friih-gmbh) — Seed
- Innovestor (https://capitalatlas.ai/funds/innovestor) — Series C
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A
- ZEISS Ventures (https://capitalatlas.ai/funds/zeiss-ventures) — Series A